Article
Medicine, General & Internal
Qiang Wu, Fanglong Li, Xiaotao Yin, Jiangping Gao, Xu Zhang
Summary: This study aimed to construct a nomogram for predicting prostate cancer in patients with PSA <= 20 ng/mL at initial biopsy, which was developed based on predictors assessed by multivariable logistic regression analysis and validated through receiver operating characteristic curve, calibration plots, and decision curve analysis. The nomogram showed high predictive accuracy and could avoid unnecessary biopsies for 42.5% of patients while missing only 4.4% of PCa cases.
Article
Oncology
Wenming Ren, Yujie Xu, Congcong Yang, Li Cheng, Peng Yao, Shimin Fu, Jie Han, Dong Zhuo
Summary: This study developed and validated a nomogram to predict the probability of prostate cancer after transperineal prostate biopsy by combining patient clinical information and biomarkers. The nomogram showed good performance in predicting prostate cancer and provided clinical benefit.
FRONTIERS IN ONCOLOGY
(2022)
Article
Urology & Nephrology
Aydin Pooli, David C. Johnson, Joseph Shirk, Daniela Markovic, Taylor Y. Sadun, Anthony E. Sisk, Amirhossein Mohammadian Bajgiran, Sohrab Afshari Mirak, Ely R. Felker, Alexa K. Hughes, Steven S. Raman, Robert E. Reiter
Summary: The study showed that multiparametric magnetic resonance imaging frequently underestimates pathological tumor size, and the degree of underestimation increases with smaller radiologic tumor size and lower PI-RADSv2 scores. Therefore, a larger ablation margin may be required for smaller tumors and lesions with lower PI-RADSv2 scores. These variables must be considered when estimating treatment margins in focal therapy.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Sunao Shoji, Takatoshi Kaya, Yumiko Tanaka, Kohei Uemura, Taku Kusaka, Kumpei Takahashi, Soichiro Yuzuriha, Tatsuo Kano, Izumi Hanada, Tatsuya Umemoto, Takahiro Ogawa, Mayura Nakano, Masayoshi Kawakami, Masahiro Nitta, Masanori Hasegawa, Kazunobu Hashida, Terumitsu Hasebe, Tomonori Kaneko, Jun Okada, Satomi Asai, Akira Miyajima
Summary: The study evaluated the utility of LDN-PSA in detecting clinically significant prostate cancer in patients suspected of having it based on multiparametric magnetic resonance imaging. LDN-PSAD can serve as a biomarker for detecting suspicious lesions with PSA levels <=20 ng/mL and PI-RADS category >=3. The findings suggest that LDN-PSAD has potential clinical value in reducing unnecessary biopsies for patients with the highest PI-RADS category 3.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Xiaosong Meng, Brian Chao, Fei Chen, Richard Huang, Samir S. Taneja, Fang-Ming Deng
Summary: Benign histological features on magnetic resonance imaging targeted prostate biopsy do not predict the likelihood of missed cancer on subsequent biopsy. A high rate of downgrading in PI-RADS score is observed on repeat imaging, indicating that persistent PI-RADS 4/5 abnormalities may lead to a higher risk of missed cancer.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Shauna R. Campbell, Martin C. Tom, Shree Agrawal, Jason A. Efstathiou, Jeff M. Michalski, Matthew C. Abramowitz, Alan Pollack, Daniel E. Spratt, Jason W. D. Hearn, Kevin L. Stephans, Tianming Gao, Jianbo Li, Rahul D. Tendulkar
Summary: PSA kinetics after salvage radiotherapy are strongly associated with the risk of prostate cancer recurrence, providing valuable information for clinical management decisions.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Oncology
Jun-guang Wang, Bin-tian Huang, Li Huang, Xia Zhang, Pei-pei He, Jun-bo Chen
Summary: This study aimed to investigate the independent factors associated with extracapsular extension in prostate cancer and improve the accuracy of predicting it before surgery. The Likert scale score, biopsy grade group, and biopsy positive rate were identified as independent risk factors for extracapsular extension. Their combination significantly improved the diagnostic efficiency.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Paul F. Pinsky, Howard Parnes
Summary: Screening for prostate cancer should take into consideration the risks and benefits. PSA screening can reduce prostate cancer deaths, but the reduction is small. Follow-up tests such as biopsy and MRI may be needed for individuals with elevated PSA levels. Patients with low-risk or favorable intermediate-risk prostate cancer may choose active surveillance over immediate curative treatment. Surgery and radiation therapy have good outcomes but can lead to complications.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Lorenzo Bianchi, Paolo Castellucci, Andrea Farolfi, Matteo Droghetti, Carlos Artigas, Jose Leite, Paola Corona, Qaid Ahmed Shagera, Renata Moreira, Christian Gonzalez, Marcelo Queiroz, Felipe de Galiza Barbosa, Riccardo Schiavina, Desiree Deandreis, Stefano Fanti, Francesco Ceci
Summary: This study performed external validation of a nomogram developed to predict the results of 68Ga-labeled prostate-specific membrane antigen-11 positron emission tomography/computed tomography in recurrent prostate cancer patients. The nomogram showed excellent predictive accuracy, and it was found that performing PSMA-PET when the predicted probability is >= 20% can reduce the incidence of false negative scans.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Article
Oncology
Danielle S. Bitterman, Ming-Hui Chen, Jing Wu, Andrew A. Renshaw, Marian Loffredo, Philip W. Kantoff, Eric J. Small, Anthony V. D'Amico
Summary: This study found that low testosterone level at PSA failure in high-risk patients with PC treated with RT is associated with increased PCSM and ACM risk, and that higher PSAn is also associated with worse PCSM and ACM risk, especially in men with normal testosterone levels at PSA failure.
Article
Oncology
Ugo Giovanni Falagario, Ivan Jambor, Anna Lantz, Otto Ettala, Armando Stabile, Pekka Taimen, Hannu J. Aronen, Juha Knaapila, Ileana Montoya Perez, Giorgio Gandaglia, Nicola Fossati, Alberto Martini, Vito Cucchiara, Wolfgang Picker, Erik Haug, Parita Ratnani, Kenneth Haines, Sara Lewis, Nair Sujit, Oscar Selvaggio, Francesca Sanguedolce, Luca Macarini, Luigi Cormio, Tobias Nordstrom, Ash Tewari, Alberto Briganti, Peter J. Bostrom, Giuseppe Carrieri
Summary: The combination of PSAd and MRI findings can help avoid unnecessary prostate biopsies and reduce the risk of missing clinically significant prostate cancer. Optimal biopsy strategies should be individualized based on the risk that both patients and clinicians are willing to accept to avoid unnecessary procedures.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Oncology
Francesco Sessa, Rossella Nicoletti, Cosimo De Nunzio, Angelo Porreca, Stefano Maria Magrini, Vincenzo Mirone, Andrea Tubaro, Sergio Serni, Paolo Gontero, Marianna Noale, Stefania Maggi, Mauro Gacci
Summary: This study investigated the association between inflammation, proliferative inflammatory atrophy, and Prostate Cancer (PCa) in frustules from prostate biopsies. The results showed a significant association between prostate inflammation (PI) and PCa, suggesting that anti-inflammatory therapies may be a potential preventive approach for PCa.
Article
Urology & Nephrology
Sohail Singh, Preeti Sandhu, Kerri Beckmann, Aida Santaolalla, Kamal Dewan, Sharon Clovis, Jonah Rusere, Grace Zisengwe, Benjamin Challacombe, Christian Brown, Paul Cathcart, Rick Popert, Prokar Dasgupta, Mieke Van Hemelrijck, Oussama Elhage
Summary: This study aimed to investigate the risk of disease progression and conversion to active treatment following a negative biopsy while on active surveillance for prostate cancer. The results showed that a negative biopsy finding at the first scheduled follow-up biopsy was strongly associated with decreased risk of subsequent upgrading, clinical or radiological suspicion of disease progression, and conversion to active treatment.
Article
Endocrinology & Metabolism
Gang Liu, Yuze Zhu, Zichuan Yao, Yunzhong Jiang, Bin Wu, Song Bai
Summary: This study developed and validated a model to predict the probability of clinically significant prostate cancer in men with negative MRI results, which can assist in pre-biopsy risk stratification and inform biopsy decisions.
Article
Urology & Nephrology
Shingo Kimura, Hiromichi Katayama, Eiichiro Ohara, Hiroshi Aoki, Rie Shibuya, Hiroshi Naganuma, Shigeto Ishidoya, Akihiro Ito
Summary: The study aims to investigate the need for careful postoperative monitoring for prostate cancer after holmium laser enucleation of the prostate (HoLEP). The results suggest that HoLEP is associated with the risk of potential prostate cancer. Postoperative PSA should be carefully monitored even if not diagnosed with prostate cancer with HoLEP specimen.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)